Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS1025a in Advanced Solid Tumors
NCT07681882Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS1025a in solid tumor, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of Participants Reporting Dose-limiting Toxicities at 12 months, Number of Participants Reporting Adverse Events at 12 months and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
DS1025a
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07681882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681882.